Gemini Therapeutics, Inc. GMTX
1.35 0.00 (+0.00%)
At closeDec 30, 2022, 12:00 AM EST
1.35 Day range 1.41
52-week range unavailable
Analyst view
Consensus: hold
Hold
Price target (mean) 1.50
Ratings (-1m) 1 0 buy · 1 hold · 0 sell
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- 1 month ago 1
- 2 months ago 1
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | -0.43 | 0.0% | 0 | 0.0% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | -0.41 | 0.0% | 0 | 0.0% | 0 |
| Current year | -0.32 | -0.32 – -0.32 | -1.78 | +82.0% | 0 | 0.0% | 1 |
| Next year | -0.26 | -0.26 – -0.26 | -0.32 | +18.8% | 0 | 0.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 11, 2022 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Mar 3, 2022 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Mar 1, 2022 | Jefferies | Downgrade | Buy | Hold |
| Jan 24, 2022 | SVB Leerink | Maintained | — | Outperform |
| Dec 20, 2021 | SVB Leerink | Maintained | — | Outperform |
| Dec 15, 2021 | HC Wainwright & Co. | Initiated | — | Buy |
| Oct 6, 2021 | Goldman Sachs | Maintained | — | Buy |
| Apr 8, 2021 | SVB Leerink | Initiated | — | Outperform |
| Mar 3, 2021 | Jefferies | Initiated | — | Buy |
| Mar 2, 2021 | Goldman Sachs | Initiated | — | Buy |